Sarepta Therapeutics Inc (NASDAQ: SRPT) is 38.28% higher on its value in year-to-date trading and has touched a low of $55.25 and a high of $173.25 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SRPT stock was last observed hovering at around $133.08 in the last trading session, with the day’s gains setting it 0.26%.
Currently trading at $133.34, the stock is -5.46% and -5.38% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.01 million and changing 0.20% at the moment leaves the stock 11.01% off its SMA200. SRPT registered 16.88% gain for a year compared to 6-month gain of 7.27%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.23% loss in the last 1 month and extending the period to 3 months gives it a 0.63%, and is -2.24% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.18% over the week and 3.31% over the month.
Sarepta Therapeutics Inc (SRPT) has around 1314 employees, a market worth around $12.72B and $1.50B in sales. Current P/E ratio is 329.64 and Fwd P/E is 11.66. Profit margin for the company is 3.14%. Distance from 52-week low is 141.34% and -23.04% from its 52-week high. The company has generated returns on investments over the last 12 months (2.01%).
Sarepta Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.16 with sales reaching $408.79M over the same period.The EPS is expected to grow by 135.69% this year, but quarterly earnings will post 41.50% year-over-year. Quarterly sales are estimated to grow 23.20% in year-over-year returns.
659.0 institutions hold shares in Sarepta Therapeutics Inc (SRPT), with institutional investors hold 97.15% of the company’s shares. The shares outstanding are 93.73M, and float is at 89.53M with Short Float at 7.50%. Institutions hold 92.90% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 8.8 million shares valued at $$1.14 billion. The investor’s holdings represent 9.3581 of the SRPT Shares outstanding. As of 2024-03-31, the second largest holder is BLACKROCK INC. with 5.96 million shares valued at $$771.63 million to account for 6.3414 of the shares outstanding. The other top investors are JANUS HENDERSON GROUP PLC which holds 4.89 million shares representing 5.2041 and valued at over $$633.17 million, while CAPITAL INTERNATIONAL INVESTORS holds 5.1255 of the shares totaling 4.82 million with a market value of $$623.68 million.
Sarepta Therapeutics Inc (SRPT) Insider Activity
The most recent transaction is an insider sale by Brown Ryan Edward, the company’s EVP, General Counsel. SEC filings show that Brown Ryan Edward sold 38,957 shares of the company’s common stock on Jun 25 ’24 at a price of $161.61 per share for a total of $6.3 million. Following the sale, the insider now owns 17129.0 shares.
Sarepta Therapeutics Inc disclosed in a document filed with the SEC on Jun 24 ’24 that Arif Bilal (Chief Tech Ops Officer) sold a total of 7,859 shares of the company’s common stock. The trade occurred on Jun 24 ’24 and was made at $163.08 per share for $1.28 million. Following the transaction, the insider now directly holds 21261.0 shares of the SRPT stock.
Still, SEC filings show that on Jun 25 ’24, Arif Bilal (Chief Tech Ops Officer) disposed off 3,898 shares at an average price of $163.23 for $0.64 million. The insider now directly holds 17,363 shares of Sarepta Therapeutics Inc (SRPT).
